#1 Clinical Trials Search in Europe

Ponesimod

Ponesimod is an investigational drug that has been studied in several clinical trials for its potential in treating multiple sclerosis (MS) and other conditions. This article summarizes key findings from clinical trials evaluating the efficacy, safety, and pharmacological properties of ponesimod in various patient populations.

Table of Contents

What is Ponesimod?

Ponesimod is a medication used to treat certain types of multiple sclerosis (MS). It’s also known by other names such as ACT-128800, JNJ-67896153, and Ponvory[1]. Ponesimod belongs to a class of drugs called S1P1 receptor agonists, which work in a specific way to help manage MS symptoms[2].

How Does Ponesimod Work?

Ponesimod works by blocking the movement of certain white blood cells called T-lymphocytes. These cells are believed to play a role in the development of MS symptoms. By preventing these cells from moving freely in the body, ponesimod may help reduce inflammation and damage to the nervous system that occurs in MS[3].

What Conditions Does Ponesimod Treat?

Ponesimod is primarily used to treat relapsing forms of multiple sclerosis (RMS). This includes:

  • Relapsing-remitting multiple sclerosis (RRMS): The most common form of MS, characterized by periods of symptom flare-ups followed by periods of recovery[4].
  • Active secondary progressive multiple sclerosis (SPMS): A form of MS that develops after RRMS, where symptoms steadily worsen over time, but the person still experiences relapses[4].

Additionally, research is being conducted to explore the potential use of ponesimod in treating chronic graft versus host disease (GVHD), a condition that can occur after organ or cell transplants[3].

How is Ponesimod Administered?

Ponesimod is taken orally as a tablet, usually once daily. The typical dosing schedule involves a gradual increase in dosage over time, known as up-titration. This helps reduce the risk of certain side effects. The process usually looks like this:

  1. Starting with a low dose (usually 2 mg)
  2. Gradually increasing the dose over about two weeks
  3. Reaching a maintenance dose of 20 mg per day[5]

It’s important to take ponesimod exactly as prescribed by your healthcare provider.

Clinical Trials and Effectiveness

Several clinical trials have been conducted to evaluate the effectiveness of ponesimod in treating MS. Some key findings include:

  • Reduced relapse rates: Studies have shown that ponesimod can significantly reduce the annualized relapse rate (ARR) in patients with relapsing MS[4].
  • Slowed disability progression: Some trials have indicated that ponesimod may help slow the progression of disability in MS patients[4].
  • Reduced brain lesions: MRI scans have shown that ponesimod can reduce the number of new or enlarging brain lesions in MS patients[4].

One notable study, called OPTIMUM, compared ponesimod to another MS medication called teriflunomide and found ponesimod to be more effective in reducing relapses[6].

Potential Side Effects

Like all medications, ponesimod can cause side effects. Some of the most common include:

  • Increased liver enzyme levels: This may indicate liver stress and requires monitoring[5].
  • Decreased white blood cell count: This is actually part of how the medication works, but it needs to be monitored[5].
  • Respiratory effects: Some patients may experience a temporary decrease in lung function[5].
  • Heart rate changes: Especially when first starting the medication, ponesimod can cause a temporary decrease in heart rate[5].

Your healthcare provider will monitor you closely for these and other potential side effects.

Drug Interactions

Ponesimod can interact with other medications. Some notable interactions include:

  • Heart rate-lowering drugs: Medications like beta-blockers may enhance the heart rate-lowering effect of ponesimod[7].
  • Other MS medications: The use of ponesimod with other drugs that suppress the immune system may increase the risk of infections[7].

Always inform your healthcare provider about all medications, supplements, and herbal products you’re taking.

Ongoing Research

Research on ponesimod is ongoing, with studies looking at its long-term effectiveness and safety in MS patients. Additionally, researchers are exploring its potential use in other conditions, such as chronic graft versus host disease[3].

As with any medication, it’s crucial to discuss the potential benefits and risks of ponesimod with your healthcare provider to determine if it’s the right choice for your specific situation.

Aspect Details
Primary Conditions Studied Relapsing Multiple Sclerosis (RMS), Chronic Graft-Versus-Host Disease (GVHD)
Key Efficacy Measures Annualized Relapse Rate (ARR), Disability Progression, MRI Lesion Activity
Dosing Oral tablets, typically 20 mg daily maintenance dose with initial up-titration
Safety Monitoring Heart rate, blood pressure, ECG parameters, liver enzymes, lymphocyte counts
Pharmacokinetics Cmax, AUC, tmax, half-life evaluated in various trials
Comparators Placebo, Teriflunomide (in some MS trials)
Notable Findings Reduced relapse rates and MRI lesion activity in RMS, manageable safety profile with appropriate monitoring

FAQ

  • What is ponesimod and how does it work? Ponesimod is an oral medication that acts as a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator. It works by preventing certain types of immune cells called lymphocytes from leaving the lymph nodes, which may reduce inflammation and damage in the central nervous system in conditions like multiple sclerosis.
  • What conditions has ponesimod been studied for in clinical trials? Ponesimod has primarily been studied for the treatment of relapsing multiple sclerosis (RMS). It has also been investigated for chronic graft-versus-host disease (GVHD) in one trial.
  • How is ponesimod administered in clinical trials? In most trials, ponesimod is administered as an oral tablet once daily. The dosage is often gradually increased over time, starting with lower doses (e.g. 2 mg) and increasing to a maintenance dose (typically 20 mg) to reduce initial side effects.
  • What are some of the main outcomes measured in ponesimod clinical trials? Key outcomes measured include annualized relapse rate in MS patients, changes in disability progression, MRI measures of brain lesions, safety and tolerability, effects on heart rate and blood pressure, and pharmacokinetic parameters like maximum plasma concentration and area under the curve.
  • Are there any notable side effects or safety concerns with ponesimod? Some potential side effects observed in trials include temporary decreases in heart rate, changes in liver enzyme levels, and decreases in lymphocyte counts. Effects on heart rhythm and lung function are also closely monitored. However, the overall safety profile appears manageable with appropriate monitoring.

Ongoing Clinical Trials on Ponesimod

  • Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Annualized Relapse Rate (ARR): The average number of relapses a patient with multiple sclerosis experiences per year. It is a key measure of disease activity and treatment efficacy in MS clinical trials.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis. The EDSS scale ranges from 0 to 10 in 0.5 unit increments, with higher scores indicating greater disability.
  • Gadolinium-enhancing (Gd+) lesions: Areas of active inflammation in the brain or spinal cord that can be seen on MRI scans when a contrast agent called gadolinium is used. These lesions indicate current disease activity in MS.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. This includes measures like maximum plasma concentration (Cmax) and area under the curve (AUC).
  • QT interval: A measure of the heart's electrical cycle between the start of the Q wave and the end of the T wave in an electrocardiogram (ECG). Prolongation of the QT interval can be a safety concern with some medications.
  • Sphingosine-1-phosphate receptor 1 (S1P1): A protein receptor found on the surface of certain immune cells. Ponesimod works by modulating this receptor to alter the movement of immune cells.
  • T2 lesions: Areas of damage in the brain or spinal cord that appear bright on T2-weighted MRI scans. In MS, an increase in the number or size of T2 lesions can indicate disease progression.
  • Up-titration: The process of gradually increasing the dose of a medication over time, often used to reduce the risk of side effects when starting a new treatment.

References

  1. https://clinicaltrials.gov/study/NCT05552196
  2. https://clinicaltrials.gov/study/NCT01093326
  3. https://clinicaltrials.gov/study/NCT02461134
  4. https://clinicaltrials.gov/study/NCT03232073
  5. https://clinicaltrials.gov/study/NCT02136888
  6. https://clinicaltrials.gov/study/NCT02425644
  7. https://clinicaltrials.gov/study/NCT03882255